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Summary
Objective: The present study describes the presence and binding parameters of the A1, A2A, A2B and A3 adenosine receptors in bovine
chondrocytes and ﬁbroblast-like synoviocytes. The effect of low frequency low energy pulsed electromagnetic ﬁelds (PEMFs) on the adeno-
sine receptor afﬁnity and density was studied.
Methods: Saturation, competition binding experiments and Western blotting assays in the absence and in the presence of PEMFs on the
adenosine receptors in bovine chondrocytes or ﬁbroblast-like synoviocytes were performed. Thermodynamic analysis of the A2A or A3 binding
was studied to investigate the forces driving drugereceptor coupling. In the adenylyl cyclase and proliferation assays the potency of typical
high-afﬁnity A2A or A3 agonists in the absence and in the presence of PEMFs was evaluated.
Results: Bovine chondrocytes and ﬁbroblast-like synoviocytes expressed all adenosine receptors. PEMFs evoked an up-regulation of A2A and
A3 receptors and thermodynamic parameters indicate that adenosine binding is enthalpy and entropy driven. In PEMF-treated cells the
potency of typical A2A or A3 agonists on cyclic AMP assays was signiﬁcantly increased when compared with the untreated cells. PEMFs
potentiated the effect of A2A or A3 agonists on cell proliferation in both cell types.
Conclusions: PEMFs mediate an up-regulation of A2A and A3 receptors related to an increase of their functional activities in bovine chondro-
cytes and ﬁbroblast-like synoviocytes. No differences are present in adenosine afﬁnity and in the drugereceptor interactions. Our data could
be used as a trigger to future studies addressed to PEMFs and adenosine therapeutic intervention in inﬂammatory joint diseases.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Chronic inﬂammation is a signiﬁcant factor in the pathophys-
iology ofmany forms of joint disease. Adenosine hasbeen re-
ported to reduce inﬂammation in several in vivo models
suggesting a potential value of this purine nucleoside as
a therapeutic mediator of inﬂammatory joint disease able to
limit articular cartilage degeneration1,2. In the peripheral sys-
tem, adenosine has been shown to limit systemic
inﬂammatory responses through receptor-mediated regula-
tion of a wide variety of cell types3e7. Adenosine interacts
with four cell surface receptor subtypes named as A1, A2A,
A2B and A3, which are coupled to different G-proteins
8. A1
and A3 receptors mediate inhibition of the adenylate
cyclase activity, in contrast both A2A and A2B subtypesaThese authors contributed equally to this work
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292stimulate cAMP (cyclic AMP) accumulation8. A role of aden-
osine in modulating chondrocytes and ﬁbroblast-like
synoviocytes is documented by previous studies. In chondro-
cytes it has been reported that adenosine and its analogs
were capable of altering cAMP and nitric oxide (NO) produc-
tion1,2. In addition, it seems likely that for normal cartilage
function, extracellular adenosine levels must be quite tightly
regulated sincedepletion leads to increasedglycosaminogly-
can (GAG) release and the production of matrix metallo-
proteinases (MMPs) such as MMP-3 and MMP-13,
prostaglandin E2 (PGE2) andNO, whilst its increasemay trig-
ger chondrocyte death2,9,10. In ﬁbroblast-like synoviocytes
adenosine receptor stimulation is involved in the regulation
of MMPs11,12. Recently, in human synoviocytes it has been
reported the selective involvement of the A2A receptor sub-
type in the immunomodulatory actions of methotrexate13.
Further, in vivo adenosine A2A receptor agonists inhibit carti-
lage damage when used in the treatment of septic arthritis by
diminishing interleukin-8 expression and GAG loss and re-
duce rat adjuvant induced arthritis14e16. Although A2A and
A2B adenosine receptor transcripts have been described in
articular chondrocytes17, however, the binding parameters
such as afﬁnity and density of adenosine subtypes have not
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viocytes. Low frequency electromagnetic ﬁelds (PEMFs)
have important effects on cartilage. In particular, in vitro cul-
tured chondrocytes increase their proliferation as a function
of PEMF exposure length18,19. In cartilage explants PEMFs
increase proteoglycan synthesis preventing the catabolic ef-
fect of the pro-inﬂammatory cytokine IL-1 and acting in syn-
ergy with insulin-like growth factor I20e22. In vivo, it has
been reported that PEMFs preserve the morphology of artic-
ular cartilage, retard the development of osteoarthritic lesions
in guinea pig and actually articular cartilage immunohisto-
chemistry demonstrated that pro-inﬂammatory cytokines in-
terleukin-1 (IL-1) were down-regulated while anabolic
cytokines were up-regulated transforming growth factor
beta (TGF-b)23e27. Further, clinical studies in humans
show that PEMF stimulation has beneﬁcial effects in pa-
tients after arthroscopic surgery for cartilage lesions28.
To explain the biological effects of PEMFs it has been pro-
posed that they may inﬂuence ligand binding with cell
membrane receptors affecting also the membrane protein
distribution29. It has beenalsodemonstrated thatPEMFsevoke
an up-regulation of the A2A and A3 adenosine receptors and al-
ter the response of these receptor subtypes in human neutro-
phils30,31. Thus, the chondroprotective effects of PEMF might,
at least partially, result from an anti-inﬂammatory mechanism
of PEMFs together with adenosine receptor agonists23.
From this background, the aim of this study was to inves-
tigate the expression and binding parameters of the A1, A2A,
A2B and A3 adenosine receptors in bovine chondrocyte and ﬁ-
broblast-like synoviocyte membranes. In the same cell types
wehavealsostudied theeffectofPEMFtreatmenton theafﬁnity
and density of the A1, A2A, A2B and A3 adenosine receptors. A
thermodynamic analysis of the A2A and A3 adenosine receptor
binding was performed with the aim to investigate new insights
into the effect of PEMFs on the forces driving drugereceptor
coupling. Competition experiments, cAMP levels and cell prolif-
eration assays of A2A or A3 receptor agonists in the absence
and in the presence of PEMFs have been performed.Materials and methodsCHONDROCYTE MONOLAYER CULTURESBovine articular cartilage derived from the metacarpophalangeal joints of
14e18-month-old animals (Limousine breed). Chondrocytes were isolated
from cartilage fragments obtained from the weight-bearing region of the artic-
ular surface32. Brieﬂy, the cartilage was dissected out and cut into small
pieces. Pieces were subjected to a sequential digestion in Dulbecco’s mod-
iﬁed Eagle’s/Ham’s F12 (1:1) medium (DMEM/F12) (Gibco-Invitrogen, Pais-
ley, UK) with pronase from Streptomyces griseus (Calbiochem, Darmstadt,
Germany) for 90 min and collagenase P from Clostridium histolyticum
(Roche, Indianapolis, USA) for about 12 h. The resulting cell suspension
was ﬁltered to remove undigested cartilage. Chondrocytes were recovered
by centrifugation, counted and plated at high density (150,000/cm2) in
75 cm2 ﬂasks (Falcon, Becton Dikinson and Company, Franklin Lakes, NJ,
USA) and in multiwells (Nunc, Denmark, 6.6 6.6 cm, 1.6 cm the diameter
of each well). Chondrocytes were cultured in DMEM/F12 supplemented with
10% fetal bovine serum (FBS) and antibiotics (penicillin 100 U/ml, streptomy-
cin 0.1 mg/ml) (Gibco-Invitrogen, Paisley, UK) (complete medium). Only chon-
drocyteswithout subculturing andmaintained in culture for 1weekwereused in
the binding and functional experiments.FIBROBLAST-LIKE SYNOVIOCYTE CULTURESFibroblast-like synoviocytes were obtained by culture of the bovine syno-
vial ﬂuid. Synovial ﬂuid was aspirated from the metacarpophalangeal joints of
14e18-month-old animals by a syringe. Then, fresh synovial ﬂuid was diluted
1:4 with complete medium and plated in 25 cm2 culture ﬂasks (Falcon, Bec-
ton Dikinson and Company, Franklin Lakes, NJ, USA). After 3 h, medium
was removed and fresh complete medium was added to the ﬂasks. Cells
were maintained in culture and passaged when reaching conﬂuence. Syno-
vial cells at the third and fourth passages were used for the analysis of aden-
osine receptors.CHONDROCYTES AND FIBROBLAST-LIKE SYNOVIOCYTES’
CHARACTERIZATIONTheexpressionofaggrecan, type II and type I collagens in thesamechondro-
cyte monolayer cultures used for binding experiments was evaluated by immu-
nohistochemistryaspreviously described22. Incubationswith theprimarymouse
monoclonal antibody [6-B-4] to aggrecan (1:50) and the rabbit polyclonal to col-
lagen type II (1:200) (Abcam, Cambridge Science Park, Cambridge, UK) were
performed for 1 h at 37C.
Fibroblast-like synoviocytes were characterized by immunoﬂuorescence
staining with vimentin, a speciﬁc cellular marker for mesenchymal cells33. Cells
were ﬁxed with cold methanol, washed with phosphate buffer saline (PBS) and
incubated with the primary mouse antibody speciﬁc for the human vimentin at
1:200 dilution for 1 h at 37C. Washed slides were then incubated with a sec-
ondary ﬂuorescein isothiocyanate-conjugated goat anti-mouse antibody for
1 h at 37C in the dark. Antibodies were fromSigmaeAldrich S.r.l. (Milan, Italy).
Fluorescence was visualized using the Nikon Eclipse TE 2000-E microscope
(Nikon Instruments Spa, Sesto Fiorentino, Firenze, Italy) equippedwith a digital
camera (DXM 1200F, Nikon Instruments Spa, Sesto Fiorentino, Firenze, Italy).
To conﬁrm that ﬁbroblast-like synoviocyte cultures were not contaminated by
macrophages, CD14 expression was evaluated by reverse transcription poly-
merase chain reaction (RT-PCR). Total RNA extraction was performed using
a commercial kit. RNA conversion to cDNA was performed using the commer-
cial kit Superscript First-strand Synthesis System for RT-PCR (Invitrogen Life
Technologies, Carlsbad, CA, USA). Twomicroliters of cDNAwere ampliﬁed by
speciﬁc oligonucleotide primers for CD 14 (dp50-CTG GAA GCC GGC G-30;
rp50-AGC TGAGCAGGA ACC TGTGC-30). Primer sequences were selected
to amplify both human and bovine genome and were from separate exons to
exclude a possibly genomic DNA contamination of the RNA samples. PCR re-
actions were performed in a total volume of 25 ml containing 1 U TaqDNApoly-
merase (Roche Molecular Biochemicals, Indiana, USA), 25 pmol of each
primer, 200 mM deoxynucleotide triphosphates (dNTPs) in 1 PCR buffer
(10 mM Tris, pH 8.3, 50 mM KCl, 1.5 mM MgCl2). Cycling parameters were
as follows: 1 min at 94C, 1 min at 55C, 1 min at 72C for CD14. The size
of the ampliﬁed sequence was 403 bp. mRNA from human macrophages
was used as a positive control for CD14 expression. PCR products were ana-
lyzed on 1.5% agarose gel, stained with ethidium bromide.PREPARATION OF BOVINE CHONDROCYTE
AND FIBROBLAST-LIKE SYNOVIOCYTE MEMBRANESFor membrane preparation, the culture medium was removed the cells
were washed with PBS and scraped off T75 ﬂasks in ice-cold hypotonic
buffer (5 mM TriseHCl, 2 mM ethylendiamine tetraacetic acid (EDTA) pH
7.4). The cell suspension was homogenized by using a Polytron and was
centrifuged for 30 min at 100,000g. The membrane pellet was resuspended
in the same buffer solution used in the binding experiments, incubated with
2 IU/ml of adenosine deaminase for 30 min at 37C and centrifuged for
30 min at 100,000g. Finally the suspension was used in saturation and com-
petition binding experiments. The protein concentration was determined
according to a Bio-Rad method with bovine albumin as reference standard34.FIELD CHARACTERISTICSThe chondrocyte and ﬁbroblast-like synoviocyte membranes or mono-
layer cultures were exposed to a PEMF generated by a pair of rectangular
horizontal coils (14 23 cm) each made of 1400 turns of copper wire; coils
were powered by a pulse generator (IGEA, Italy) used in previous
works21,22,30,31. The characteristics of the ﬁeld were as follows: the pulse du-
ration of the signal was 1.3 ms and the repetition rate was 75 Hz, yielding
a duty cycle of 1/10. The intensity peak of the magnetic ﬁeld was 1.5 mT
and the induced electric ﬁeld, as detected with a standard coil probe (50 turns,
0.5 cm internal diameter of the coil probe, 0.2 cm copper diameter), was
0.07 mV/cm.
The temperature, continuously monitored by a thermoresistor within the
incubator, was constant through the exposure time and exactly maintained
during the binding and functional experiments.WESTERN BLOTTING OF ADENOSINE RECEPTORSChondrocytes and ﬁbroblast-like synoviocytes untreated or PEMF-treated
were harvested and washed with ice-cold PBS containing 1 mM sodium ortho-
vanadate, 104 mM 4-(2-aminoethyl)-benzenesulfonyl ﬂuoride, 0.08 mM aproti-
nin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, and 1.4 mM E-64.
Then cells were lysed in Triton lysis buffer and the protein concentration was de-
termined using bicinchoninic acid (BCA) protein assay kit (Pierce, Illinois, USA).
Aliquots of total protein sample (50 mg) were analyzed using antibodies speciﬁc
for human A1, A2A, A2B and A3 adenosine receptors (1 mg/ml dilution)
35. Filters
were washed and incubated for 1 h at room temperature with peroxidase-conju-
gated secondary antibodies (1:2000 dilution). Speciﬁc reactions were revealed
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sham Biosciences, New York, USA).SATURATION AND COMPETITION BINDING EXPERIMENTS
TO ADENOSINE RECEPTORSThe chondrocyte and synoviocyte membranes were PEMF treated for the
speciﬁc incubation times relative to the A1, A2A, A2B and A3 binding
experiments30,31.
Saturation binding experiments to A1 adenosine receptors were per-
formed according to the method described previously using [3H]-1,3-di-
propyl-8-cyclopentyl-xanthine ([3H]-DPCPX, speciﬁc activity 120 Ci/mmol;
NEN-Perkin Elmer Life and Analytical Sciences, USA) as radioligand36. The
membranes derived from PEMFs-treated or untreated chondrocytes or ﬁbro-
blast-like synoviocytes (100 mg of protein/assay) with 8e10 concentrations
of the radioligand [3H]-DPCPX (0.01e20 nM) were incubated in TriseHCl
50 mM, pH 7.4, for 90 min at 4C. Nonspeciﬁc binding was determined in the
presence of DPCPX 1 mM. Saturation binding experiments to A2A adenosine
receptors were performed according to themethod described previously using
[3H]-4-(2-[7-amino-2-(2-furyl)[1,2,4] triazolo [2,3-a] [1,3,5] triazin-5-yl-amino]-
ethyl ([3H]-ZM 241385, speciﬁc activity 27.4 Ci/mmol; American Radiolabeled
Chemicals Inc, Saint Louis, MO, USA) as radioligand5. The membranes de-
rived fromPEMFs-treatedor untreated chondrocytes or ﬁbroblast-like synovio-
cytes (100 mg of protein/assay) were incubated for 60 min at 4C with 8e10
concentrations of the radioligand [3H]-ZM 241385 (0.01e20 nM) andTriseHCl
50 mM,MgCl2 10 mM, pH7.4.Nonspeciﬁc bindingwas determined in the pres-
ence of ZM241385 1 mM.Saturation binding experiments to A2B adenosine re-
ceptors were performed using [3H]-N-benzo [1,3[dioxol-5-yl-2-[5-(2,6-dioxo-
1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl-
oxy]-acetamide ([3H]-MRE 2029F20, speciﬁc activity 123 Ci/mmol; Amer-
sham International Chemical Laboratories, Buckinghamshire, UK) as ra-
dioligand37. The membranes obtained as previously described (100 mg of
protein/assay) with 8e10 concentrations of [3H]-MRE 2029F20 in the range
0.01e20 nM were incubated in TriseHCl 50 mM, MgCl2 10 mM, EDTA
1 mM, pH 7.4 at 4C for 60 min. Nonspeciﬁc binding was determined in
the presence of MRE 2029F20 1 mM. Saturation binding experiments to
A3 adenosine receptors were performed using [
3H]-5N-(4-methoxyphenylcar-
bamoyl) amino-8-propyl-2-(2-furyl) pyrazolo [4,3-e]-1,2,4-triazolo [1,5-c]pyrimi-
dine ([3H]-MRE 3008F20, speciﬁc activity 67 Ci/mmol; Amersham
International Chemical Laboratories, Buckinghamshire, UK) as radioligand38.
The membranes treated as above mentioned (100 mg of protein/assay) with
8e10 concentrations in the range0.01e50 nMof [3H]-MRE3008F20were incu-
bated in TriseHCl 50 mM, MgCl2 10 mM, EDTA 1 mM, pH 7.4, at 4
C for
150 min. Nonspeciﬁc binding was determined in the presence of MRE
3008F20 1 mM. In competition experiments, carried out to determine the A2A
or A3 afﬁnity values, 1 nM of [
3H]-ZM 241385 or 2 nMof [3H]-MRE3008F20, bo-
vine chondrocyte or ﬁbroblast-like synoviocyte membranes (100 mg of protein
per assay) and at least 6e8 different concentrations of 2-[p-(2-carboxyethyl)-
phenetyl-amino]-50-N-ethyl-carboxamido adenosine (CGS 21680, Sigma-RBI,
St. Louis,MO,USA)orN 6-(3-iodobenzyl)2-chloroadenosine-50-N-methylurona-
mide (Cl-IB-MECA, Sigma-RBI, St. Louis, MO, USA) as typical A2A or A3 aden-
osine agonists were incubated at 4C for 60 or 150 min, respectively. In
saturation or competition binding experiments, at the end of the incubation
time, bound and free radioactivity was separated by ﬁltering the assay mixture
through Whatman GF/B glass ﬁber ﬁlters by using a Brandel cell harvester.
The ﬁlter bound radioactivity was counted by Scintillation Counter Packard Tri
Carb 2500 TR with an efﬁciency of 58%.THERMODYNAMIC ANALYSISFor a generic binding equilibrium LþR¼ LR (L¼ ligand, R¼ receptor) the
afﬁnity association constant KA¼ 1/KD is directly related to the standard free
energyDG (DG ¼ RT ln KA) which can be separated in its enthalpic and en-
tropic contributions according to the Gibbs equation:DG ¼DH   TDS. The
standard free energy was calculated as DG ¼ RT ln KA at 298.15 K, the
standard enthalpy, DH , from the van’t Hoff plot lnKA vs (1/T ) (the slope is
DH /R) and the standard entropy as DS ¼ (DH  DG)/T with
T¼ 298.15 K and R¼ 8.314 J/K/mol39. KA values were obtained from satura-
tion experiments of [3H]-ZM 241385 or [3H]-MRE 3008F20 binding to the hu-
man PEMF-treated or untreated bovine chondrocyte and ﬁbroblast-like
synoviocyte membranes carried out at 0, 10, 15, 20, 25 and 30C in
a thermostatic bath assuring a temperature of 0.1C.MEASUREMENT OF cAMPLEVELS INBOVINECHONDROCYTES
OR FIBROBLAST-LIKE SYNOVIOCYTESPEMF-treated or untreated bovine chondrocytes or ﬁbroblast-like synovio-
cytes (106 cells/ml) were suspended in 0.5 ml incubation mixture Krebs
Ringer phosphate buffer, containing 1.0 IU/ml adenosine deaminase and
0.5 mM 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro 20-1724) asphosphodiesterase inhibitor and preincubated for 10 min in a shaking bath at
37C. Then the effect of a typical A2A adenosine agonist was studied by using
CGS 21680 at different concentrations (1 nMe1 mM) that was added to the mix-
ture for a further5 min. Insimilar experimental conditions, theeffect ofN-ethylcar-
boxamidoadenosine (NECA) on adenosine nonselective agonist was studied.
To evaluate the effect of a typical A3 adenosine agonist, forskolin 1 mM and Cl-
IB-MECA at different concentrations (0.1 nMe100 nM) were added to the mix-
ture and the incubation continued for a further 5 min. The effect of a selective
A2A or A3 antagonist such as 7-(2-phenylethyl)-2-furyl)pyrazolo [4,3-e]-1,2,4-tri-
azolo-[1,5-c] pyrimidine (SCH 58261) (1 mM) or MRE 3008F20 (1 mM) on CGS
21680(1 mM)orCl-IB-MECA(100 nM)wasevaluated, respectively. The reaction
was terminated by the addition of cold 6% trichloroacetic acid (TCA). The cells
were also incubated with forskolin (1 mM) and/or Ro 20-1724 (0.5 mM) to evalu-
ate the adenylyl cyclase activity. The TCA suspensionwas centrifuged at 2000g
for 10 min at 4C and the supernatant was extracted four times with water satu-
rated diethyl ether. The ﬁnal aqueous solution was tested for cAMP levels
through a competition protein binding assay by using [3H]-cAMP as radioligand
(speciﬁc activity 21 Ci/mmol, NEN Research Products, Boston, MA, USA)30.
Samples of cAMPstandards (0e10 pmol) were added to each test tube contain-
ing trizma base 0.1 M, aminophylline 8.0 mM, mercaptoethanol 6.0 mM, pH 7.4
and [3H]-cAMP (at the ﬁnal concentration of 1 nM). The binding protein, previ-
ously prepared from beef adrenals, was added to the samples and incubated
at 4C for 150 min.At theendof the incubation timeandafter the additionof char-
coal the samples were centrifuged at 2000g for 10 min. The clear supernatant
was mixed with 4 ml of Atomlight and counted in a Scintillation Counter Packard
Tri Carb 2500 TR.PEMF RESPONSE SPECIFICITYBinding to a2 adrenergic receptors was carried out with [
3H]-UK 14304
(0.2e10 nM) on bovine chondrocytes or ﬁbroblast-like synoviocytes in
a 50 mM TriseHCl buffer, pH 7.4 containing MgCl2 10 mM for 60 min at
25C. Nonspeciﬁc binding was determined with 1 mM of UK 14304. Binding
to b2 adrenergic receptors was carried out with [
3H]-CGP 12177
(0.1e10 nM) on bovine chondrocytes or ﬁbroblast-like synoviocytes in
a 50 mM TriseHCl buffer, pH 7.4 containing MgCl2 10 mM for 60 min at
25C. Nonspeciﬁc binding was determined with 1 mM of CGP 12177. The ef-
fects of isoproterenol (1 nMe10 mM) on stimulation of adenylate cyclase activ-
ity was evaluated to verify if PEMFs involve the functionality of another G-
protein coupled receptors30.[3H] THYMIDINE INCORPORATIONChondrocytes or ﬁbroblast-like synoviocytes were treated with CGS
21680 and Cl-IB-MECA (10 mM) in complete medium containing adenosine
deaminase (ADA) and 1 mCi/ml [3H] thymidine. Parallel cultures were ex-
posed to PEMF. Cells cultured in the absence of adenosine agonists and
PEMF exposure were used as controls. After 24 h of labeling cells were tryp-
sinized, and [3H] thymidine was evaluated as previously described35. In all
cultures, cell viability was evaluated by the Trypan blue exclusion test40.STATISTICAL ANALYSISA weighted nonlinear least-squares curve ﬁtting program Ligand41 was
used for computer analysis of saturation and competition binding experi-
ments. Functional experiments were calculated by nonlinear regression anal-
ysis using the equation for a sigmoid concentrationeresponse curve
(GraphPAD Prism, San Diego, CA, USA). Analysis of data was done with
Student’s t test (unpaired analysis). Differences were considered signiﬁcant
at a value of P< 0.01. All data are reported as mean S.E.M. of independent
experiments (n¼ 3e6 as indicated in Results).ResultsPHENOTYPE CHARACTERIZATION OF BOVINE
CHONDROCYTES AND FIBROBLAST-LIKE SYNOVIOCYTESChondrocytes, cultured in monolayer, show phenotypic
instability and can dedifferentiate toward the ﬁbroblast phe-
notype shifting from the synthesis of type II to type I colla-
gen22. When analyzed by immunohistochemistry, under
the same experimental conditions of binding experiments,
chondrocytes stained positive for aggrecan and type II col-
lagen, speciﬁc markers of the chondrocytic phenotype, and
resulted negative for type I collagen, which is expressed in
dedifferentiated chondrocytes (Fig. 1). Negative controls,
obtained without primary antibodies, did not show any stain-
ing. Fibroblast-like synoviocytes used in our experiments
Fig. 1. Immunohistochemistry for aggrecan (A), type II (B) and
type I (C) collagens of bovine chondrocytes cultured in monolayers.
Nuclei were counterstained by hematoxylin.
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Fig. 2. Expression of vimentin in synovial ﬁbroblasts (A) (original
magniﬁcation 20). Analysis of CD14 mRNA expression (B upper
panel) in macrophages (MC) and in bovine ﬁbroblast-like synovio-
cytes (FS). M is 100 bp DNA ladder (Biolabs). One microgram of
total RNA was loaded for lane and stained with ethidium bromide
to conﬁrm equal RNA quantity used for RT-PCR (B lower panel).
295Osteoarthritis and Cartilage Vol. 16, No. 3showed the expression of vimentin, the main intermediate
ﬁlament protein in mesenchymal cells and synovial ﬁbro-
blast [Fig. 2(A)]. Results obtained by RT-PCR showed the
absence of CD14, thus indicating the absence of contami-
nating macrophages in our cultures [Fig. 2(B)].WESTERN BLOTTINGFigure 3(A) shows the immunoblot signals of A1, A2A and
A2B adenosine receptors in bovine chondrocytes and ﬁbro-
blast-like synoviocytes in the absence and in the presence
of PEMF. The intensity of each band in immunoblot assay
was quantiﬁed using molecular analyst/PC densitometry
software (Bio-Rad). Mean densitometry data from three in-
dependent experiments were normalized to control that
was set to 100% [Fig. 3(B,C)]. Interestingly, in both the cells
examined only A2A adenosine receptors was altered in the
presence of PEMFs showing a fold of increase statistically
signiﬁcant from 1.45 to 1.65 (*, P< 0.02). Unfortunately
Western blot of A3 adenosine receptors was undetectable
probably due to the low degree of homology between
bovines and humans.SATURATION BINDING EXPERIMENTS IN BOVINE
CHONDROCYTES AND FIBROBLAST-LIKE SYNOVIOCYTESA series of experiments were carried out to determine the
effect of PEMFs on the binding parameters of A1, A2A, A2B
and A3 adenosine receptors in bovine chondrocytes and ﬁ-
broblast-like synoviocytes. All experiments were performed
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Fig. 3. Western blotting analysis of bovine chondrocytes and ﬁbroblast-like synoviocytes in the absence and in the presence of PEMFs for A1,
A2A and A2B adenosine receptors (A). Each band was quantiﬁed by using molecular analyst/PC densitometry software (Bio-Rad). Mean den-
sitometry data from three independent experiments were normalized to control from chondrocytes (B) and ﬁbroblast-like synoviocytes (C).
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ous studies30,31 where no effect of PEMFs on adenosine re-
ceptors in human neutrophils was observed under 0.5 mT
and the maximum effect appeared from 1 to 3.5 mT reaching
a stable plateau. Table I reports the afﬁnity (KD, nM) and den-
sity (Bmax, fmol/mg protein) of A1, A2A, A2B and A3 adenosine
receptors in bovine chondrocyte and in ﬁbroblast-like syno-
viocyte membranes untreated or exposed to PEMF. The
afﬁnity values were strictly similar in both PEMF-treated or
untreated cells (n¼ 4). Moreover also the Bmax values
(n¼ 4) of A1 and A2B adenosine receptors did not change in
the presence of PEMFs (Table I). On the contrary the Bmaxvalues of A2A and A3 adenosine receptors were altered after
the PEMF treatment. Figures 4 and 5 report a saturation
curve of [3H]-ZM 241385 binding to A2A adenosine receptors
in bovine chondrocyte [Fig. 4(A)] and in ﬁbroblast-like syno-
viocyte [Fig. 5(A)] membranes untreated or treated with
PEMFs. Figures 4 and 5 show also a saturation curve of
[3H]-MRE 3008F20 binding to A3 adenosine receptors in bo-
vine chondrocyte [Fig. 4(C)] and in ﬁbroblast-like synoviocyte
[Fig. 5(C)] membranes untreated or treated with PEMFs,
respectively. The Scatchard plot analysis of A2A adenosine
receptors indicated the presence of a single class of binding
sites with a KD value of 1.71 0.32 nM and a Bmax value of
Table I
Saturation binding experiments on adenosine receptors in bovine chondrocyte and in fibroblast-like synoviocyte membranes
Chondrocyte membranes Fibroblast-like synoviocyte membranes
KD (nM) Bmax (fmol/mg protein) KD (nM) Bmax (fmol/mg protein)
A1 adenosine receptors
Controls 2.18 0.22 41 2 0.67 0.01 30 2
PEMF 2.17 0.16 40 3 0.68 0.03 31 3
A2A adenosine receptors
Controls 1.71 0.32 53 5 2.05 0.17 76 6
PEMF 2.25 0.24 100 8* 2.52 0.20 181 11*
A2B adenosine receptors
Controls 2.19 0.24 51 3 1.21 0.13 84 5
PEMF 2.02 0.14 55 3 1.18 0.08 78 6
A3 adenosine receptors
Controls 4.61 0.35 79 5 1.86 0.22 83 4
PEMF 4.48 0.15 183 8* 2.08 0.09 185 6*
Data are expressed as the mean S.E.M. (n¼ 4 or 6 independent experiments as indicated in Results); *, P< 0.01 vs controls.
297Osteoarthritis and Cartilage Vol. 16, No. 353 5 fmol/mg protein in untreated bovine chondrocyte
[n¼ 6; Fig. 4(B)]. In bovine chondrocyte membranes treated
with PEMFs the KD value was 2.25 0.24 nM and the Bmax
value was 100 8* fmol/mg protein [*, P< 0.01 vs controls,
n¼ 6; Fig. 4(B)]. TheScatchard plot analysis of A3 adenosine
receptors indicated the presence of a single class of binding
sites with a KD value of 4.61 0.35 nM and a Bmax value of
79 5 fmol/mg protein in untreated bovine chondrocyte
[n¼ 6; Fig. 4(D)]. In bovine chondrocyte treated with PEMFs
the KD value was 4.48 0.15 nM and the Bmax value was0 5 10 15 20
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298 K. Varani et al.: Adenosine receptors in chondrocytes and synoviocyteswere 2.52 0.20 nMand 181 11* fmol/mg protein, respec-
tively [*,P< 0.01 vs controls, n¼ 6; Fig. 5(B)]. TheScatchard
plot analysis of A3 adenosine receptors in the same cells
treated with PEMFs indicated the presence of a single class
of binding sites with a KD value of 2.08 0.09 nM and a Bmax
value of 185 6* fmol/mg protein [*, P< 0.01 vs controls,
n¼ 6; Fig. 5(D)].THERMODYNAMIC STUDIESSaturation experiments were performed at 0, 10, 15, 20, 25
and 30C and the Scatchard plots resulted to be linear in the
concentration range investigated (n¼ 3). In untreated bovine
chondrocyte or in ﬁbroblast-like synoviocyte membranes KD
values of [3H]-ZM 241385 or [3H]-MRE 3008F20 binding to
A2A or A3 adenosine receptors increased with the increase
of investigated temperatures. While the dissociation con-
stant (KD) changed with temperature, Bmax values of A2A or
A3 adenosine receptors appeared to be largely independent
of it. Figure 6 shows the van’t Hoff of ln KA vs 1/T for [
3H]-ZM
241385 or [3H]-MRE 3008F20 binding to the A2A or A3 aden-
osine receptors in untreated or PEMF-treated bovine
chondrocyte [Fig. 6(A,B)] or in ﬁbroblast-like synoviocyte
membranes [Fig. 6(C,D)]. The ﬁnal equilibrium thermody-
namic parameters of A2A adenosine receptors (expressed
as mean values S.E.M. of three independent experiments)
in untreated bovine chondrocyte membranes were as follows:
DG ¼47.27 0.14 kJ/mol;DH ¼38.92 3.53 kJ/mol and
DS ¼ 28.78 2.84 J/mol/K. The thermodynamic parameters of
A3 adenosine receptors in untreated bovine chondrocytemembranes were as follows: DG ¼ 47.80 0.16 kJ/mol;
DH ¼ 33.93 3.42 kJ/mol and DS ¼ 44.48 4.25 J/mol/K.
The ﬁnal equilibrium thermodynamic parameters of A2A
adenosine receptors in untreated bovine ﬁbroblast-like
synoviocyte membranes were as follows: DG ¼
47.22 0.11 kJ/mol; DH  ¼ 35.22 3.77 kJ/mol and
DS ¼ 30.71 3.03 J/mol/K. The thermodynamic parame-
ters of A3 adenosine receptors in untreated bovine ﬁbro-
blast-like synoviocyte membranes were as follows: DG ¼
48.12 0.14 kJ/mol; DH  ¼ 35.59 3.67 kJ/mol and
DS ¼ 42.08 4.15 J/mol/K. Similar results were also ob-
tained in bovine chondrocyte or ﬁbroblast-like synoviocyte
membranes treated with PEMFs suggesting that the ﬁnal
equilibrium thermodynamic parameters in the examined sub-
strates were not inﬂuenced by the PEMF treatment and indi-
cating that the binding to A2A or A3 adenosine receptors was
enthalpy and entropy driven.COMPETITION BINDING EXPERIMENTS IN BOVINE
CHONDROCYTES AND FIBROBLAST-LIKE SYNOVIOCYTESFigure 7 shows the competition curves of CGS 21680
(A,C) and Cl-IB-MECA (B,D) in untreated or PEMF-treated
bovine chondrocyte or in ﬁbroblast-like synoviocyte mem-
branes, respectively. The afﬁnity (Ki) of CGS 21680 or Cl-IB-
MECA in untreated bovine chondrocyte membranes was
28 3 or 2.6 0.3 nM, respectively (n¼ 4). In parallel stud-
ies, performed in the same cell membranes treated with
PEMFs, CGS 21680 or Cl-IB-MECA had a Ki value of
25 2 or 2.9 0.3 nM, respectively (n¼ 4). In untreated
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Fig. 6. Van’t Hoff plot showing the effect of temperature on the equilibrium binding association constant, KA¼ 1/KD of [3H]-ZM 241385 to A2A
adenosine receptors (A,C) or [3H]-MRE 3008F20 to A3 adenosine receptors (B,D) in untreated or PEMF-treated bovine ﬁbroblast-like syno-
viocyte membranes, respectively. The plots are essentially linear in the temperature range investigated (4e30C). Binding experiments were
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299Osteoarthritis and Cartilage Vol. 16, No. 3ﬁbroblast-like synoviocyte membranes CGS 21680 or Cl-IB-
MECA showed a Ki value of 30 3 or 3.3 0.3 nM,
respectively (n¼ 4). In PEMF-treated ﬁbroblast-like synovio-
cyte membranes CGS 21680 or Cl-IB-MECA revealed a Ki
valueof27 2or3.5 0.3 nM, respectively (n¼ 4).Thecom-
petition curves of both the agonists examined, performed in
the absence and in the presence of PEMFs, exhibited Hill co-
efﬁcients near the unity and were best described by the exis-
tence of one high-afﬁnity binding site.PEMF RESPONSE SPECIFICITYTo verify that PEMF activity is speciﬁc to A2A and A3
adenosine receptors, we studied other types of membrane
receptors coupled to G-proteins. The expression of a2 and
b2 adrenergic receptors in PEMF-treated and untreated
bovine chondrocytes or in ﬁbroblast-like synoviocytes was
determined by performing saturation binding experiments
using [3H]-UK 14304 or [3H]-CGP 12177, respectively. A
single saturation binding site was detected for adrenergic
receptors in untreated or PEMF-treated bovine chon-
drocytes or in ﬁbroblast-like synoviocytes. In bovine
chondrocytes or in ﬁbroblast-like synoviocytes, saturation
of [3H]-UK 14304 binding shows a KD value of 2.18 0.15 or
2.06 0.11 nM and a Bmax value of 18 2 or 23 3 fmol/
mg protein, respectively. In the same cells, [3H]-CGP 12177
exhibitshighafﬁnity forb2 adrenergic receptorswithaKD value
of 2.05 0.12 or 2.07 0.10 nMand aBmax value of 20 2 or
26 3 fmol/mg protein, respectively. None of these binding
were signiﬁcantly affected by PEMFs in bovine chondrocytes
(a2 adrenergic receptors:KD¼ 2.25 0.05 nM;Bmax¼ 20 2fmol/mg protein; b2 adrenergic receptors: KD¼ 2.13 0.16
nM; Bmax¼ 21 2 fmol/mg protein) or in ﬁbroblast-like sy-
noviocytes (a2 adrenergic receptors: KD¼ 2.18 0.20 nM;
Bmax¼ 24 3 fmol/mg protein; b2 adrenergic receptors:
KD¼ 2.11 0.16 nM;Bmax¼ 28 3 fmol/mg protein). In addi-
tion, in bovine chondrocytes and in ﬁbroblast-like synovio-
cytes, isoproterenol stimulated cAMP levels showing EC50
values of 250 30 and 282 26 nM, respectively. PEMFs in
the same cell types did notmodify the potency of isoproterenol
(EC50¼ 237 24 and 267 23 nM, respectively).cAMP ASSAYS IN BOVINE CHONDROCYTES
AND FIBROBLAST-LIKE SYNOVIOCYTESThe A2A adenosine receptors are coupled to stimulation
of adenylate cyclase via Gs stimulatory proteins, which
leads to an increase of cAMP formation. Untreated or
PEMF-treated bovine chondrocyte or ﬁbroblast-like synovial
cells did not reveal change of basal enzyme activity and of
the response of adenylate cyclase activator forskolin. No
change in cAMP production was also observed in the ab-
sence or in the presence of the cAMP-dependent phospho-
diesterase inhibitor, Ro 20-1724 (Table II). We have also
evaluated the effect of a typical A2A adenosine agonist
such as CGS 21680 on the adenylate cyclase activity.
When CGS 21680 was incubated with PEMF-treated or
untreated examined cells an ampliﬁcation of adenylate
cyclase response was detected revealing a signiﬁcant in-
crease of cAMP production in a concentration-dependent
manner. As shown in Fig. 8 the log dose response curve
for CGS 21680 in control and in PEMF-treated bovine
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Fig. 7. Competition experiments of speciﬁc [3H]-ZM 241385 to A2A adenosine receptors (A,C) or [
3H]-MRE 3008F20 binding to A3 adenosine
receptors (B,D) of CGS 21680 or Cl-IB-MECA in untreated and PEMF-treated bovine chondrocytes (A,B) or ﬁbroblast-like synoviocyte (C,D)
membranes. Competition experiments were performed as described in Materials and methods (n¼ 4).
300 K. Varani et al.: Adenosine receptors in chondrocytes and synoviocyteschondrocytes or in ﬁbroblast-like synoviocytes revealed
a shift vs left of the curve suggesting an increase in
cAMP production after PEMF treatment. In particular CGS
21680 elicited a stimulation of cAMP levels in untreated or
PEMF-treated bovine chondrocytes with an EC50 of
82 7 and 46 5* nM, respectively [*, P< 0.01,
Fig. 8(A)]. Moreover, CGS 21680 elicited a stimulation of
cAMP levels in untreated or PEMF treated in ﬁbroblast-
like synoviocytes with an EC50 of 91 8 and 54 6* nM,
respectively [*, P< 0.01, Fig. 8(C)]. The selective A2A an-
tagonist SCH 58261 (1 mM) totally inhibited the rise in
cAMP levels induced by CGS 21680 (1 mM) suggesting
that the stimulatory effect was essentially A2A mediated
(n¼ 4, Table II).
On the contrary, the A3 adenosine receptors are coupled to
inhibition of adenylyl cyclase via Gi proteins, which leads to
decreases of cAMP formation. We have also evaluated the
inhibitory effect of a typical A3 adenosine agonist like Cl-IB-
MECA on the adenylyl cyclase activity. When forskolin
(1 mM) and the agonist were incubated with PEMF-treated
or untreated neutrophils, a reduction of adenylyl cyclase re-
sponse was detected revealing a signiﬁcant decrease of
cAMP production in a concentration-dependent manner
(n¼ 4, Fig. 8). Cl-IB-MECA determined a decrease of
cAMP levels in untreated or PEMF-treated bovine chon-
drocytes with an IC50 values of 6.33 0.64 and
3.37 0.31* nM, respectively [*, P< 0.01, n¼ 4, Fig. 8(B)].
Moreover Cl-IB-MECA induced a decrease of cAMP levels
in untreated or PEMF-treated ﬁbroblast-like synoviocytes
with an IC50 values of 7.90 0.71 and 4.03 0.42* nM,respectively [*, P< 0.01, n¼ 4, Fig. 8(D)]. The selective A3
antagonist MRE 3008F20 (1 mM) antagonized Cl-IB-MECA
(100 nM)mediated cAMP inhibition suggesting that the inhib-
itory effect was essentially A3 mediated (n¼ 4, Table II).
NECA, a typical adenosine receptor agonist, determines
a stimulation of cAMP levels in untreated or PEMF-treated
bovine chondrocytes with an EC50 value of 40 3 or
66 5* nM, respectively (*, P< 0.01). Analogous results
were obtained in ﬁbroblast-like synoviocytes with an EC50
value of 37 3 and 59 5* nM, respectively (*, P< 0.01).
This stimulatory effect due to the interaction of NECA with
A2A and A2B adenosine receptors predominates on the in-
hibitory effect mediated by A1 and A3 adenosine receptors.CELL PROLIFERATION AND VIABILITYChondrocytes or ﬁbroblast-like synoviocytes treated with
CGS 21680 or Cl-IB-MECA (10 mM) showed no statistically
signiﬁcant modulation of cell proliferation. However, in ﬁbro-
blast-like synoviocytes, Cl-IB-MECA induced a slight reduc-
tion of cell proliferation. PEMF exposure did not modify cell
proliferation in the absence of adenosine agonists with re-
spect to controls. Interestingly, in the presence of PEMFs,
CGS 21680 induced an increase on cell proliferation in
both cells which was signiﬁcant in ﬁbroblast-like synovio-
cytes. Analogously, the inhibitory effect of Cl-IB-MECA
was increased by PEMFs (Fig. 9). In all tested conditions
cell viability was not changed with respect to control
conditions (99% viable cells).
Table II
Basal and stimulated cAMP production in bovine chondrocytes and in fibroblast-like synoviocytes
Chondrocytes (pmol cAMP 106 cells) Fibroblast-like synoviocytes (pmol cAMP 106 cells)
Control PEMF treatment Control PEMF treatment
Basal levels 10 1 11 1 11 1 12 1
þ Ro 20-1724 (0.5 mM) 25 2 27 2 23 2 24 2
þ CGS 21680 (1 mM) A2A stimulation 51 4 80 6* 50 4 78 6*
þ CGS 21680 (1 mM) 27 2 28 2 25 2 26 2
þ SCH 58261 (1 mM)
Forskolin (1 mM) 98 10 95 9 96 9 97 10
Forskolin (1 mM) Ro 20-1724 (0.5 mM) 120 12 115 13 112 11 118 12
þ Cl-IB-MECA (100 nM) A3 inhibition 82 6 45 5* 84 6 46 5*
þ Cl-IB-MECA (100 nM) 116 11 110 12 108 11 114 10
þMRE 3008F20 (1 mM)
Data are expressed as the mean S.E.M. (n¼ 4 independent experiments); *, P< 0.01 vs controls.
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The purpose of the current investigation was to document
the presence and the binding parameters of adenosine re-
ceptor subtypes in bovine chondrocytes or in ﬁbroblast-
like synoviocytes and to evaluate the effect of PEMFs on
adenosine receptors in these cell types. Preliminary charac-
terization of cells used in our experiments showed the ex-
pression of chondrocyte and synoviocyte phenotypic
markers, as well as the absence of contaminating cells in
ﬁbroblast-like synoviocyte cultures22.
Our pharmacological data in unexposed cells report that
A1, A2A, A2B and A3 receptors are expressed and similarly
distributed in both cell types showing high-afﬁnity values-10 -9 -8 -7 -6 -5
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bovine chondrocytes (A,B) or ﬁbroblast-like synoviocytes (C,D). cAMP experin the nanomolar range and a receptor density from 30 to
83 fmol/mg of protein. After PEMF treatment A1 and A2B re-
ceptors show similar binding parameters with respect to un-
treated cells. A single class of A2A and A3 binding sites with
a similar afﬁnity in untreated or PEMF-treated examined
cells was found according to saturation binding experiments
performed with [3H]-ZM241385 or [3H]-MRE 3008F20, re-
spectively. On the contrary, the number of binding sites in
PEMF-treated bovine chondrocytes or in ﬁbroblast-like syn-
oviocytes was increased signiﬁcantly (P< 0.01) vs the con-
trol conditions. These data revealed that the predominant
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iments were performed as described in Materials and methods (n¼ 4).
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Fig. 9. Proliferation activity measured by [3H] thymidine incorpora-
tion assay. Bovine chondrocytes (A) or ﬁbroblast-like synoviocytes
(B) were treated with CGS 21680 and Cl-IB-MECA at 10 mM
concentration.
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through Western blotting analysis that conﬁrmed binding
data described above showing no differences for A1 and
A2B receptors and a statistically signiﬁcant increase for
A2A receptors in PEMF-treated cells compared to controls.
As a consequence of the saturation binding experiments
we have selectively studied A2A or A3 adenosine receptor
binding site and the mechanism of interaction with typical
adenosine ligands. Thermodynamic parameters obtained
from the van’t Hoff plot indicate that [3H]-ZM 241385 or
[3H]-MRE 3008F20 binding to A2A and A3 adenosine recep-
tors is enthalpy and entropy driven, with a major contribu-
tion of the enthalpic component in agreement with data
obtained in other cells expressing human adenosine recep-
tors or by using typical adenosine antagonists6,7,31,37,38.
Further, the ﬁnal thermodynamic parameters in the exam-
ined substrates were not inﬂuenced by PEMF treatment sug-
gesting that no alteration in the drugereceptor interaction
was found.
The results obtained in competition binding experiments
show that the afﬁnity of CGS 21680 or Cl-IB-MECA in the
PEMF-treated bovine chondrocytes or in ﬁbroblast-like syn-
oviocytes were strictly similar to those obtained in untreated
cells conﬁrming that the treatment did not modify the druge
receptor interaction and afﬁnity values of these agonists. In
addition, the saturation binding experiments performed on
other G-protein coupled receptors such as a2 and b2adrenergic subtypes suggest that PEMFs did not modify
the binding parameters. The capability of isoproterenol to
stimulate adenylate cyclase activity and to determine an in-
crease of cAMP levels is not modiﬁed by the presence of
PEMFs suggesting that the response to PEMF is strictly
linked to A2A and A3 adenosine receptors. A similar PEMF
speciﬁcity was also reported in human neutrophils30.
Another purpose of the present study was to investigate if
the increase in A2A or A3 adenosine receptor binding sites
induced by PEMF treatment might be related to a modula-
tion of receptor functional activities. To this aim, we ana-
lyzed the effects of A2A and A3 agonists on adenylyl
cyclase activity and cell proliferation in the absence and in
the presence of PEMF treatment.
Our results did not show any change of basal enzyme ac-
tivity and of the response of adenylyl cyclase to the direct
activator forskolin used in the absence or in the presence
of cAMP-dependent phosphodiesterase inhibitor (Ro 20-
1724). Forskolin, which directly activated adenylate cyclase
was utilized in this study as a positive control for cAMP pro-
duction. Ro 20-1724, a type IV phosphodiesterase inhibitor
prevented the rapid degradation of cAMP allowing the accu-
rate detection of the cAMP levels produced. Moreover, we
have evaluated the capability of typical A2A or A3 adenosine
agonists such as CGS 21680 or Cl-IB-MECA to modulate
cAMP levels. These compounds showed potency values
in the nanomolar range, in agreement with their afﬁnity in
binding experiments. Interestingly, in the PEMF-treated bo-
vine chondrocytes or in ﬁbroblast-like synoviocytes the po-
tency of CGS 21680 or Cl-IB-MECA, respectively, in
stimulating and inhibiting cAMP production, were signiﬁ-
cantly increased when compared with the untreated cells.
To further conﬁrm that the effects induced by the agonists
on cAMP formation were due to the modulation of adeno-
sine receptors by PEMFs, we performed experiments in
the presence of typical selective A2A or A3 adenosine antag-
onists such as SCH 58261 or MRE 3008F20. These antag-
onists in the presence or in the absence of PEMFs were
able to prevent the effect of cAMP induced by CGS
21680 or Cl-IB-MECA through a selective modulation of
the adenylyl cyclase via the A2A or A3 receptors, respec-
tively. In addition, the levels of cAMP increased in response
to NECA, a nonselective agonist, suggesting that in physio-
logical condition (presence of endogenous adenosine) the
activation of A2A may prevail over the A3 mediated inhibitory
action. This is not surprising because a similar behavior has
already been reported in other substrates6,7.
In line with cAMP data, PEMFs did not modify cell prolif-
eration in the absence of adenosine agonists and in the
presence of ADA. On the other hand, previous studies re-
port that PEMFs, in the absence of ADA, can increase
cell proliferation18,19. On the contrary, in the presence of
CGS 21680, PEMF exposure was able to stimulate cell pro-
liferation. Further, Cl-IB-MECA inhibited slightly cell prolifer-
ation in ﬁbroblast-like synoviocytes and this effect was
potentiated by PEMF exposure. Collectively, our results
on cAMP and cell proliferation assays show that the in-
crease in adenosine binding sites induced by PEMFs is cor-
related to an increase of A2A or A3 activity in the presence of
adenosine receptor agonists. In conclusion, the novel ﬁnd-
ings of this study in bovine chondrocytes and ﬁbroblast-
like synoviocytes are as follows: (1) identiﬁcation and
binding characterization of adenosine receptors; (2) up-
regulation of A2A and A3 adenosine receptors by PEMFs
but not of A1 and A2B; (3) alteration of cAMP levels and
cell proliferation by PEMFs related to the increase of A2A
and A3 adenosine receptor density; (4) similar afﬁnity of
303Osteoarthritis and Cartilage Vol. 16, No. 3typical A2A and A3 agonists in the absence or in the pres-
ence of PEMFs; (5) no changes by PEMFs in the drugere-
ceptor interaction through thermodynamic analysis.
These results identify for the ﬁrst time a molecular target
for PEMFs and provide a rational base to suggest a potential
anti-inﬂammatory role of PEMFs mediated by adenosine re-
ceptors in chondrocytes and ﬁbroblast-like synoviocytes.
The modulation of PEMFs on A2A and A3 receptors may
help to explain previous data showing that in vitro PEMF ex-
posure protects bovine full-thickness cartilage explants
from the catabolic effect of pro-inﬂammatory cytokine IL-1
and in vivo prevents osteoarthritis (OA) progression in
DunkineHartley guinea pigs23,27. It is to note that the effects
of PEMFs may be different in pathologic conditions as age
differences in response to physical forces have been re-
ported42. On the other hand PEMF exposure has a chondro-
protective effect on OA progression in DunkineHartley
guinea pigs of different age and OA severity23,24. Further
clinical studies have demonstrated a positive effect of
PEMF stimulation in patients after knee arthroscopy or suf-
fering from knee OA28,43.
Although additional studies are needed to fully under-
stand the relationship between adenosine-mediated
anti-inﬂammatory effects44,45 and PEMF exposure, our re-
sults open interesting perspectives to develop new anti-
inﬂammatory approaches in local joint disease treatment.References
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